ClinicalTrials.Veeva

Menu

Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma (PDT)

A

Asan Medical Center

Status and phase

Unknown
Phase 2

Conditions

Adverse Events
Feasibility
Treatment Response

Treatments

Procedure: Photodynamic therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT02725073
ERCP-PDT

Details and patient eligibility

About

To determine the safety and efficacy of photodynamic therapy with a novel photosensitizer and a flexible laser probe in locally advanced hilar cholangiocarcinoma.

Full description

Photodynamic therapy (PDT) is a way of producing tissue necrosis with light after prior administration of a photosensitizing agent. The most important advantages include the possibility of combining PDT with other target therapies and repeat the process as needed with a favorable outcomes. The combination of diverse therapeutic modalities is one of the new strategies to enhance oncologic treatments for pancreatic cancer. In order to overcome the limitations of each treatment modalities and to prevent the development of resistance, the application of PDT combined with target therapies, without increasing the toxicity for the patient, is being widely investigated.

PDT has been only extensively studied for the treatment of various superficial skin cancers in the Europe but not available in the United States and Japan due to the overlapping treatment fields. In Korea, the use of first-generation and second-generation photosensitizers are part of the study of Gastroenterology, Dermatology, Otolaryngology, and Gynecology.

Recently, although the investigators have introduced PDT using novel photosensitizers has not yet been used for the treatment of pancreatic cancers. This study aim to determine the safety and efficacy of photodynamic therapy with a novel photosensitizer in locally advanced hilar cholangiocarcinoma.

Enrollment

32 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Locally advanced cholangiocarcinoma confirmed to be unsuitable for surgical resection
  2. Exhibiting disease progression without distant metastasis after conventional chemoradiation therapy at multidisciplinary team discussion in Asan Medical Center
  3. Pathologically proven cholangiocarcinoma
  4. have a negative pregnancy test if appropriate
  5. ECOG(Eastern Cooperative Oncology Group) Score 0-2
  6. patients to give informed consent and age more than >19 years

Exclusion criteria

  1. age less than 18 years
  2. previous history of PDT
  3. uncorrectable coagulopathy
  4. refuse to participate
  5. pregnancy
  6. recent participation in another clinical research trial within 30 days
  7. presence of porphyria or hypersensitivity to photosensitizer
  8. Creatinine clearance < 45ml

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

32 participants in 1 patient group

photodynamic therapy
Experimental group
Description:
Photodynamic therapy with a novel photosensitizer and flexible laser catheter
Treatment:
Procedure: Photodynamic therapy

Trial contacts and locations

2

Loading...

Central trial contact

Do Hyun Park, MD, PhD; Jun Ho Choi, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems